U.S. markets close in 4 hours 49 minutes
  • S&P 500

    3,766.45
    -16.83 (-0.44%)
     
  • Dow 30

    30,124.66
    -149.21 (-0.49%)
     
  • Nasdaq

    11,120.37
    -28.27 (-0.25%)
     
  • Russell 2000

    1,755.44
    -7.25 (-0.41%)
     
  • Crude Oil

    88.56
    +0.80 (+0.91%)
     
  • Gold

    1,720.70
    -0.10 (-0.01%)
     
  • Silver

    20.54
    -0.00 (-0.02%)
     
  • EUR/USD

    0.9840
    -0.0045 (-0.45%)
     
  • 10-Yr Bond

    3.8280
    +0.0690 (+1.84%)
     
  • GBP/USD

    1.1181
    -0.0140 (-1.24%)
     
  • USD/JPY

    144.8290
    +0.2190 (+0.15%)
     
  • BTC-USD

    20,069.05
    +164.78 (+0.83%)
     
  • CMC Crypto 200

    457.00
    -6.12 (-1.32%)
     
  • FTSE 100

    6,993.63
    -58.99 (-0.84%)
     
  • Nikkei 225

    27,311.30
    +190.77 (+0.70%)
     

NanoVibronix Sets Date for Annual Shareholder Meeting

·1 min read

ELMSFORD, N.Y., September 14, 2022--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV) (the "Company"), announced today that its annual meeting of shareholders (the "Annual Meeting") will take place at 10 a.m. Eastern time on December 15, 2022. The Company will hold the Annual Meeting virtually via the internet.

The record date for determination of shareholders entitled to vote at the Annual Meeting is October 17, 2022.

The Company anticipates sending proxy materials for the Annual Meeting to stockholders in November 2022.

About NanoVibronix, Inc.

NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The Company’s primary products include PainShield® and UroShield®, which are portable devices suitable for administration at home without assistance of medical professionals. Additional information about NanoVibronix is available at: www.nanovibronix.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005953/en/

Contacts

Investors
Brett Maas, Managing Principal, Hayden IR, LLC
brett@haydenir.com
(646) 536-7331